Related Experiment Video
Updated: Jun 6, 2025
07:20
Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
Published on: January 28, 2014
36.3K
ADNI Biomarker Core: A review of progress since 2004 and future challenges
Leslie M Shaw1, Magdalena Korecka1, Edward B Lee1
1Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|November 30, 2024
Summary
The Alzheimer's Disease Neuroimaging Initiative (ADNI) Biomarker Core has biobanked and analyzed biofluid samples for Alzheimer's disease (AD) biomarkers. Collaborations advanced the detection and tracking of AD pathology using validated assays.
Area of Science:
- Neuroscience
- Biomarker Discovery
- Clinical Diagnostics
Background:
- The Alzheimer's Disease Neuroimaging Initiative (ADNI) Biomarker Core has managed biobanking and analysis of cerebrospinal fluid (CSF), plasma, and serum samples since 2004.
- Activities include sample management, biomarker analysis, and pre-analytical assessments.
Purpose of the Study:
- To describe the major activities of the ADNI Biomarker Core from 2004 to 2024.
- To review biobanking, sample distribution, and analytical methods for Alzheimer's disease (AD) biomarkers.
- To discuss collaborations and challenges in AD biomarker detection and progression monitoring.
Main Methods:
- Biobanking of CSF, plasma, and serum samples.
- Analysis of AD biomarkers using validated immunoassay and mass spectrometry-based assays.
- Performance comparisons across different biofluid and assay platforms.
Main Results:
- Shift from CSF to plasma analysis as qualified assays became available.
- Enriched participant database with performance data for AD pathology detection.
- Enabled longitudinal assessments of disease progression.
Conclusions:
- Close collaboration with academic and industrial partners is crucial for validating and implementing AD biomarkers.
- Successful implementation of AD biomarkers aids early disease detection in clinical trials and practice.
- Progress has been made in co-pathology detection and modeling disease progression within the ATN scheme.
Related Concept Videos
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
103
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
103
01:28Preclinical Development: Overview
4.2K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.2K
01:26Drug Discovery: Overview
7.5K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.5K
01:33Proteomics
7.2K
A proteome is the entire set of proteins that a cell type produces. We can study proteomes using the knowledge of genomes because genes code for mRNAs, and the mRNAs encode proteins. Although mRNA analysis is a step in the right direction, not all mRNAs are translated into proteins.
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term...
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term...
7.2K
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
59
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
59
01:11Clinical Trials: Overview
2.8K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.8K